The Utility of Subcutaneous Methotrexate for Chronic Plaque Psoriasis in a Real-World Setting.

The Utility of Subcutaneous Methotrexate for Chronic Plaque Psoriasis in a Real-World Setting. Br J Dermatol. 2019 Nov 12;: Authors: Hollywood A, O'Keeffe C, Boggs J, Feighery C, Collins S Abstract The advent of biologic agents that target cytokines central to the psoriatic disease cascade have revolutionised the treatment of moderate to severe psoriasis. Methotrexate (MTX) remains the recommended first-line conventional systemic treatment for moderate to severe psoriasis.1 This is due to its well established efficacy, safety profile and low cost1 . Across published data, MTX demonstrates a PASI 75 of approximately 40% at weeks 12-162 , with a median drug survival of 1.8 years.3 The cost of oral MTX is less than 1%, and subcutaneous (SC) MTX less than 10% of that of the cheapest biologic agent in the Republic of Ireland. Oral MTX may be limited by its toxicity and drug survival.3. PMID: 31715016 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research